Nomograms demonstrated strong predictive performance, with C-indexes around 0.70 to 0.72 and 5- and 10-year areas under the curve ranging from 0.713 to 0.759 in training and validation cohorts.
The narrative emphasizes the critical role of a supportive partner in managing chronic small lymphocytic lymphoma over 16 ...
Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...
What study showed data for zanubrutinib in previously untreated CLL? Mazyar Shadman, MD, MPH: The SEQUOIA study was a larger ...
Lori A. Leslie, MD, and Hoshiyuki Iida, APN, provide an overview of chronic lymphocytic leukemia and the risk stratification process. Lori A. Leslie, MD: Hello, and welcome to CURE Expert Connections® ...
The FDA approved zanubrutinib for treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma. Zanubrutinib (Brukinsa, BeiGene) is a selective next-generation Bruton tyrosine kinase ...
The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of certain patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The ...
—The subtype of lymphoma and the timing of anticancer treatment was shown to directly affect the level of seroconversion in cancer patients administered COVID vaccination. Reviewed by Catherine E. Lai ...
Risk of invasive fungal infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors: A TriNetX-based retrospective cohort study from 2000-2025. Propensity ...
Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal ...
Patients with chronic lymphocytic leukemia (CLL) had significantly lower monocyte-to-lymphocyte ratio values compared with healthy controls. A comparison of the second-generation Bruton tyrosine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback